ExplainersSurgical robotics

How does DEPLOY track the 2026 da Vinci SureForm gray-reload Class I recall?

DEPLOY tracks the [2026 da Vinci SureForm gray-reload Class I recall](https://registry.deploy.report/incidents/davinci-sureform-gray-reload-recall-death-2026) at primary-source-anchored FDA-recall-database verification depth as the surgical cohort's most severe verified incident. The substrate: 8mm SureForm 30 Gray reloads (2mm staples for extra-thin tissue) produced incomplete staple lines on blood vessels despite a 'completed' fire indication; customer letter / quarantine March 11, 2026; FDA classified Class I (reported May 2026); 1 death + 4 serious injuries (bleeding). Blue/white reloads UNAFFECTED at canonical within-product-family verification scope distinction. The framework reads the incident at four substrate layers simultaneously: incident-recall actuarial depth per Phase 3 Dim 1 (severity=critical at primary-source-anchored verification; cohort's most severe); within-entity verification scope at sub-product-line granularity (gray vs blue/white reload distinction is the within-da-Vinci feature-level verification posture distinct); regulatory clearance per jurisdiction at Dim 4 (FDA Class I primary-government-record sub-tier verification); year-discipline framework distinguishing the 2026 gray-reload recall from the 2022 SureForm fragment recall (Z-0340-2023; Class II; October 7, 2022) at year-class-failure-mode granularity. Cap-flag honest-absence at exact recall Z-number + unit count (not captured from primary FDA pages). Root cause stated 'still under investigation' at primary-source-anchored verification depth.

1 death + 4 serious

Patient impact at primary-source FDA-recall-database verification depth

FDA Class I

Most severe FDA recall classification; reported May 2026

March 11 2026

Customer letter / quarantine date at primary-source-anchored verification

Gray reloads affected

8mm SureForm 30 Gray; blue/white UNAFFECTED (within-product-family scope)

Z-number absent

Exact Z-number + unit count cap-flag honest-absence at primary FDA pages

Mid-2026

Snapshot date

Tier legend:VerifiedAbsence

The incident at primary-source-anchored verification depth

Per Agent A's surgical incidents substrate, the 2026 da Vinci SureForm gray-reload Class I recall operates at primary-source FDA-recall-database verification depth. The verified substrate:

  • Product affected: 8mm SureForm 30 Gray reloads (2mm staples for extra-thin tissue). Blue/white reloads UNAFFECTED at verified-by-disclosure primary-source verification depth.
  • Failure mode: incomplete staple lines on blood vessels despite a 'completed' fire indication.
  • Customer notification: customer letter and quarantine instruction issued March 11, 2026.
  • FDA classification: Class I (reported May 2026); the most severe FDA recall classification (reasonable probability of serious adverse health consequences or death).
  • Patient impact: 1 death + 4 serious injuries (bleeding).
  • Root cause: stated 'still under investigation' at primary-source verification posture; no root-cause-determined disclosure at primary-source depth.

The framework reads the incident at the verification depth where each fact actually resolves: the product distinction (gray vs blue/white), the failure mode, the customer notification date, the FDA classification, and the patient impact all operate at primary-source FDA-recall-database verification depth. The root cause operates at honest-absence cap-flag depth pending further FDA primary-source verification.

Cohort's most severe incident: Phase 3 Dim 1 actuarial signal canonical worked example

The 2026 SureForm gray-reload incident operates as the canonical actuarial signal at Phase 3 Dim 1 (deployment-incident-recall actuarial depth) per DEPLOY's robot insurance methodology pillar. The verified-base substrate per the four-dimension framework: 61 incidents at primary-source severity + root-cause + regulatory-action depth; severity spread (moderate 21, serious 20, minor 13, critical 7); the 2026 gray-reload incident operates within the 7-critical severity tier.

Per the actuarial framework, the incident operates as the cohort's most severe verified incident at three composing layers:

  • Severity: critical at primary-source-anchored verification depth; one death + four serious injuries at typed-record-disclosure depth.
  • Regulatory action: FDA Class I primary-government-record sub-tier verification per the 9-tier source-quality rubric; Class I is the most severe FDA recall classification.
  • Form factor: surgical; the surgical cohort carries 11 of the 61 verified incidents at Agent A substrate-completeness depth; the 2026 gray-reload incident is the cohort's most severe at primary-source-anchored verification within the surgical form factor.

Per the robot insurance methodology pillar's canonical discipline, honest "insurability unknown for this region / no exposure data" beats fabricated rate. The framework reads the incident at the verified numerator depth (1 death + 4 serious injuries verified at primary-source FDA-recall-database) while the exposure denominator operates at honest-absence cap-flag (no deployment-hours / units-in-service / vessels-stapled data published at the deployment-tier specific to gray-reload usage). The framework does not infer a rate-per-deployment-hour from incident count alone; rate derivation operates only where exposure substrate exists.

Within-entity verification scope: gray vs blue/white reload distinction

The 2026 SureForm gray-reload incident operates as canonical worked example for DEPLOY's verified-vs-claimed at within-entity granularity methodology pillar. The within-da-Vinci product-family substrate carries multiple SureForm reload variants: gray (2mm staples for extra-thin tissue), blue, and white. The 2026 Class I recall operates at sub-product-line granularity: gray reloads affected; blue/white reloads UNAFFECTED at primary-source verification depth.

The within-entity verification scope distinction matters editorially at three layers:

  • Per-variant verification posture: the gray reload carries recall-recorded verification posture; the blue/white reloads carry unaffected-verified posture. The framework reads per-variant verification at the feature-level depth where each variant actually resolves.
  • Aggregator collapse risk: trade-press coverage frequently frames the recall as a 'da Vinci SureForm recall' without the gray-vs-blue/white distinction. The framework distinguishes them structurally; the verification depth operates at sub-product-line granularity, not at aggregate product-family depth.
  • Insurability implication: per the robot insurance framework Dim 4 (regulatory clearance per jurisdiction), the per-variant recall status operates at insurability-per-deployment granularity; deployments using gray reloads carry recall-recorded verification posture distinct from deployments using blue/white reloads.

This is the canonical within-entity verification scope pattern at sub-product-line depth, parallel to the canonical Apple Watch SpO2 vs wellness-only feature distinction and the Whoop BPI sleep-cleared vs blood-pressure Warning Letter distinction documented at the verified-vs-claimed at within-entity granularity methodology pillar.

Year-discipline framework: distinguishing 2026 gray-reload from 2022 fragment recall

Per Agent A's surgical incidents substrate, the 2026 SureForm gray-reload recall is structurally distinct from the 2022 SureForm fragment recall. Both involve da Vinci SureForm staplers; both involve recall actions; the framework reads them as distinct at four substrate axes simultaneously:

  • Year: 2026 (gray-reload) vs 2022 (fragment) โ†’ distinct primary-source verification anchors at different temporal scope.
  • Class: Class I (gray-reload; reasonable probability of serious adverse health consequences or death) vs Class II (fragment; Z-0340-2023; recoverable adverse health consequence at higher reversibility).
  • Failure mode: incomplete staple lines on blood vessels (gray-reload) vs intraoperative device-fragment generation (fragment).
  • Affected product variant: 8mm SureForm 30 Gray reloads (gray-reload) vs da Vinci Xi 8mm SureForm 30 curved-tip staplers and reloads (fragment).

The framework reads year-class-failure-mode-variant as the canonical distinguishing pattern at incident-record granularity. Aggregator coverage that collapses 'SureForm recall' across years operates outside primary-source-anchored verification of the distinct incident records. Per cap-flag-as-trust-signal, the year-discipline framework operates at the same primary-source verification posture as any other entity-identification correction: distinct incidents at distinct years carry distinct verification anchors.

Cap-flag honest-absence at exact Z-number + unit count

Per Agent A's surgical incidents substrate, the 2026 gray-reload recall carries explicit cap-flag honest-absence at two specific claim layers:

  • Exact recall Z-number: not captured from primary FDA pages at Agent A substrate-completeness depth. The framework reads the Z-number at honest-absence cap-flag pending further FDA primary-source verification.
  • Exact unit count: affected_units_count not captured at primary-source verification depth. The framework reads the unit count at honest-absence cap-flag pending further FDA primary-source verification or Intuitive IR disclosure.

The cap-flag honest-absence operates at the same primary-source verification discipline as any other cap-flag in the framework. Per the Moon Maestro K240598 reconciliation pattern, when primary-source verification surfaces the exact Z-number or unit count at FDA-recall-database depth, the framework operates the inline editorial-transparency footer pattern + reconciliation discipline. Until primary-source verification surfaces, the framework holds the cap-flag at honest-absence depth.

Root cause under investigation: verification posture at honest-absence depth

Per Agent A's primary-source-anchored verification, the root cause of the 2026 SureForm gray-reload incident is stated 'still under investigation' at the primary-source verification depth. The framework reads root cause at honest-absence cap-flag depth: no root-cause-determined disclosure at primary-source depth means the framework does not infer a root cause from speculation or secondary-source narrative.

Per DEPLOY's verified-vs-claimed framework, root cause honest-absence operates as substantive editorial state. The framework reads under-investigation as substantive structural state subject to ongoing investigation outcome verification; not as proxy for an unverified inferred cause.

The honest-absence at root cause matters editorially at three layers:

  • Manufacturer accountability scope: per the robot insurance methodology pillar Dim 2 (manufacturer financial-state / counterparty risk), the under-investigation root cause status operates at honest-absence cap-flag for manufacturer-accountability disclosure depth; framework does not infer manufacturer culpability from incident occurrence alone.
  • Component failure mode tracking: per the robot insurance methodology pillar Dim 3 (supply-chain component failure analysis), the under-investigation status operates at honest-absence cap-flag for component-failure-mode classification; the absence of root-cause disclosure means the framework does not classify the failure mode at typed-record depth.
  • Insurability implication: per Phase 3 Dim 4 (regulatory clearance per jurisdiction), the under-investigation root cause status operates as substrate for ongoing FDA verification; the framework reads regulatory action status as verified at FDA Class I disclosure depth while root cause verification operates at honest-absence cap-flag depth.

Cross-property bidirectional discipline

Per DEPLOY's methodology cluster as AEO citation graph discipline, the 2026 SureForm gray-reload framework-in-action narrative operates within the cross-property bidirectional linking discipline:

The cross-property linking discipline compounds at the AEO citation graph layer. Institutional partners + AI assistants + downstream consumers navigating the incident encounter the methodology pillar canonical references + the Phase 3 actuarial framework + the within-entity verification scope discipline at unified verification posture.

Why this catch matters editorially

Per DEPLOY's restraint-IS-the-product discipline, the 2026 SureForm gray-reload framework-in-action narrative operates at editorial-credibility depth rather than at incident-reporting depth. The framework reads the incident at four substrate layers simultaneously (incident-recall actuarial + within-entity verification scope + year-discipline + cap-flag honest-absence); each layer composes at primary-source-anchored verification depth.

Institutional partners audit DEPLOY's framework discipline at the operational-practice layer, not just the stated-methodology layer. The verification-posture statement at /verified-vs-claimed describes the framework abstractly. The robot insurance methodology pillar describes the Phase 3 actuarial framework. This piece operates at narrative-canonical depth: how the catch composed across substrate layers (Phase 3 Dim 1 + within-entity scope + year-discipline + cap-flag honest-absence); what the discipline was (primary-source-anchored verification + cap-flag-as-trust-signal recursive application); what the editorial outcome was (canonical worked example of cohort's most severe incident at primary-source verification depth without root-cause speculation); and what the broader pattern is (the framework cuts uniformly at every substrate layer).

The catch demonstrates the discipline operationally at editorial-anchor depth. Not because the catch is exceptional. Because the catch is what the discipline does. Cohort's most severe at primary-source-anchored verification; root cause honest-absence at primary-source verification depth; gray vs blue/white reload distinction at within-product-family granularity; 2026 distinct from 2022 at year-class-failure-mode-variant granularity. The verification protocol doesn't relax at any substrate layer.

For the canonical Intuitive Surgical entity anchor where the SureForm stapler product-family operates within da Vinci scope, see what is Intuitive Surgical da Vinci. For the canonical robot insurance methodology pillar where Phase 3 Dim 1 actuarial framework operates, see How DEPLOY thinks about robot insurance. For the canonical within-entity granularity methodology pillar where per-variant verification scope discipline operates, see verified-vs-claimed at within-entity granularity. For the methodology editorial canonical reference, see how DEPLOY verifies. For the surgical cluster framework, see the surgical robotics cluster.

Substrate axis2026 gray-reload (this piece)2022 fragment recall (distinct)Framework discipline

Year

2026 (customer letter Mar 11; Class I reported May)

2022 (Z-0340-2023; initiated Oct 7)

Year as primary-source-anchored verification distinguisher

FDA classification

Class I (reasonable probability serious health consequences or death)

Class II (recoverable adverse health consequence)

Class-tier at primary-government-record sub-tier verification

Failure mode

Incomplete staple lines on blood vessels despite 'completed' fire indication

Intraoperative device-fragment generation; potential staple deployment failure

Failure-mode at primary-source-anchored typed-record disclosure

Affected product variant

8mm SureForm 30 Gray reloads (2mm staples for extra-thin tissue)

da Vinci Xi 8mm SureForm 30 curved-tip staplers and reloads

Within-product-family granularity at sub-product-line scope

Patient impact

1 death + 4 serious injuries (bleeding)

Recoverable adverse health consequence (lower severity than 2026)

Severity at primary-source typed-record verification depth

Cap-flag

Exact Z-number + unit count + root cause = honest-absence

Z-0340-2023 verified; framework discipline applied uniformly

Cap-flag-as-trust-signal recursive application

Source: Agent A surgical incidents substrate (primary-source FDA-recall-database verification) + DEPLOY's verified-vs-claimed framework applied at year-class-failure-mode-variant granularity.

Frequently asked questions

How does DEPLOY track the 2026 da Vinci SureForm gray-reload Class I recall?

At primary-source-anchored FDA-recall-database verification depth as the surgical cohort's most severe verified incident. The substrate: 8mm SureForm 30 Gray reloads (2mm staples for extra-thin tissue) produced incomplete staple lines on blood vessels despite a 'completed' fire indication; customer letter / quarantine March 11, 2026; FDA classified Class I (reported May 2026); 1 death + 4 serious injuries (bleeding). Blue/white reloads UNAFFECTED at primary-source verification depth. The framework reads the incident at four substrate layers simultaneously: incident-recall actuarial depth per Phase 3 Dim 1; within-entity verification scope at sub-product-line granularity; regulatory clearance per jurisdiction at Dim 4; year-discipline framework distinguishing the 2026 gray-reload from the 2022 SureForm fragment recall.

Why is this the cohort's most severe incident?

Per Agent A's surgical incidents substrate, the verified-base substrate carries 61 incidents at primary-source severity + root-cause + regulatory-action depth (moderate 21, serious 20, minor 13, critical 7). The 2026 gray-reload incident operates within the 7-critical severity tier at three composing layers: severity (critical at primary-source-anchored verification depth; one death + four serious injuries at typed-record-disclosure depth); regulatory action (FDA Class I primary-government-record sub-tier verification per the 9-tier source-quality rubric; Class I is the most severe FDA recall classification); form factor (surgical; the surgical cohort carries 11 of the 61 verified incidents at Agent A substrate-completeness depth; the 2026 gray-reload incident is the cohort's most severe at primary-source-anchored verification within the surgical form factor).

Why are gray reloads affected but blue/white UNAFFECTED?

Per Agent A's primary-source-anchored verification, the within-da-Vinci product-family substrate carries multiple SureForm reload variants. Gray reloads (8mm SureForm 30 Gray; 2mm staples for extra-thin tissue) produced the incomplete staple lines on blood vessels that triggered the Class I recall. Blue/white reloads carry unaffected-verified posture at primary-source verification depth. The within-entity verification scope distinction operates at sub-product-line granularity; per-variant verification posture matters editorially (gray recall-recorded vs blue/white unaffected-verified); aggregator collapse risk (trade-press 'da Vinci SureForm recall' framing without gray-vs-blue/white distinction operates outside primary-source-anchored verification); insurability implication (per the robot insurance methodology pillar Dim 4 regulatory clearance per jurisdiction, per-variant recall status operates at insurability-per-deployment granularity).

How does this differ from the 2022 SureForm recall?

Per Agent A's surgical incidents substrate, the 2026 SureForm gray-reload recall is structurally distinct from the 2022 SureForm fragment recall at four substrate axes simultaneously. Year: 2026 vs 2022. Class: Class I (reasonable probability of serious adverse health consequences or death) vs Class II (Z-0340-2023; recoverable adverse health consequence at higher reversibility). Failure mode: incomplete staple lines on blood vessels vs intraoperative device-fragment generation. Affected product variant: 8mm SureForm 30 Gray reloads vs da Vinci Xi 8mm SureForm 30 curved-tip staplers and reloads. The framework reads year-class-failure-mode-variant as the canonical distinguishing pattern at incident-record granularity; aggregator coverage that collapses 'SureForm recall' across years operates outside primary-source-anchored verification of the distinct incident records.

What is the root cause of the 2026 SureForm gray-reload incident?

Per primary-source-anchored verification, the root cause is stated 'still under investigation'. The framework reads root cause at honest-absence cap-flag depth: no root-cause-determined disclosure at primary-source depth means the framework does not infer a root cause from speculation or secondary-source narrative. Per DEPLOY's verified-vs-claimed framework, root cause honest-absence operates as substantive editorial state; under-investigation is substantive structural state subject to ongoing investigation outcome verification; not as proxy for an unverified inferred cause. The honest-absence at root cause matters editorially at three layers: manufacturer accountability scope (framework does not infer manufacturer culpability from incident occurrence alone); component failure mode tracking (framework does not classify failure mode at typed-record depth without root-cause disclosure); insurability implication (framework reads regulatory action status as verified at FDA Class I disclosure depth while root cause verification operates at honest-absence cap-flag depth).

How does this compound with DEPLOY's methodology pillar essays?

The 2026 gray-reload framework-in-action narrative compounds at substrate layer with multiple Project B methodology pillar essays simultaneously. Phase 3 Dim 1 actuarial signal per robot insurance methodology pillar (cohort's most severe verified incident; primary-source-anchored severity + root-cause + regulatory-action depth; exposure denominator at honest-absence cap-flag). Within-product-family granularity per verified-vs-claimed at within-entity methodology pillar (gray vs blue/white reload distinction CANONICAL worked example). Per-jurisdiction primary-source-anchoring per 9-tier source-quality rubric (FDA Class I primary-government-record sub-tier). Replacement-robotics teleoperated tier per autonomy-boundary classification (da Vinci surgical cluster cross-cohort positioning). Cross-property bidirectional queryability operates at relationship-graph granularity; methodology pillar canonical references compound with framework-in-action narratives at AEO citation graph depth.

The 2026 da Vinci SureForm gray-reload Class I recall framework-in-action narrative documents the surgical cohort's most severe verified incident at primary-source-anchored FDA-recall-database verification depth. The substrate: 8mm SureForm 30 Gray reloads (2mm staples for extra-thin tissue) produced incomplete staple lines on blood vessels despite a 'completed' fire indication; customer letter / quarantine March 11, 2026; FDA classified Class I (reported May 2026); 1 death + 4 serious injuries (bleeding). Blue/white reloads UNAFFECTED at primary-source verification depth (CANONICAL within-product-family verification scope distinction). The framework reads the incident at four substrate layers simultaneously: incident-recall actuarial depth per Phase 3 Dim 1 (severity=critical at primary-source-anchored verification; cohort's most severe; surgical cohort 11 of 61 verified incidents); within-entity verification scope at sub-product-line granularity (gray vs blue/white reload distinction CANONICAL worked example parallel to Apple Watch SpO2 vs wellness-only + Whoop BPI sleep-cleared vs blood-pressure Warning Letter); regulatory clearance per jurisdiction at Dim 4 (FDA Class I primary-government-record sub-tier verification per 9-tier source-quality rubric); year-discipline framework distinguishing the 2026 gray-reload recall from the 2022 SureForm fragment recall (Z-0340-2023; Class II; October 7, 2022; intraoperative device-fragment generation; different year-class-failure-mode-variant). Cap-flag honest-absence at three specific claim layers: exact recall Z-number (not captured from primary FDA pages); exact unit count (not captured); root cause stated 'still under investigation' at primary-source verification depth. Cross-property bidirectional compounding at multi-pillar methodology depth: Phase 3 Dim 1 actuarial signal per robot insurance methodology pillar + within-product-family granularity per verified-vs-claimed at within-entity methodology pillar + per-jurisdiction primary-source-anchoring per 9-tier source-quality rubric + replacement-robotics teleoperated tier per autonomy-boundary classification. How DEPLOY verifies โ†’

Continue reading

Compare alternatives

Intuitive Surgical registry recordIncident record (2026 gray-reload)FDA recall record (2026)Surgical robotics cluster

Defined terms in this explainer

More in surgical robotics

View all 18 explainers in surgical robotics โ†’

โ† All explainers